Shared on01 Aug 25Fair value Increased 8.76%
The consensus analyst price target for PTC Therapeutics has increased despite the company’s future P/E rising and net profit margin declining, indicating higher investor expectations for growth and raising the fair value estimate from $62.81 to $67.38. What's in the News FDA approved SEPHIENCE (sepiapterin) for treating phenylketonuria (PKU) in adults and children, with broad labeling and demonstrated efficacy and safety from Phase 3 and extension studies.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 0.22%
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 33.6x to 37.3x.
Shared on09 Apr 25Fair value Increased 0.11%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 118%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Increased 2.45%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.